A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Clinical trial NCT04965493 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04965493
Sponsor: Loxo Oncology, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2021-09-20
Primary completion: 2026-10-01
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.